Evaluation of the accumulation in 223Ra (Xofigo) therapy to patients with castration-resistant prostate cancer having bone metastases and determination of a suitable methodology for planar and SPECT imagings with 223Ra

Evaluation of the accumulation in 223Ra (Xofigo) therapy to patients with castration-resistant prostate cancer having bone metastases and determination of a suitable methodology for planar and SPECT imagings with 223Ra - Evaluation of the accumulation in 223Ra (Xofigo) therapy to patients with castration-resistant prostate cancer having bone metastases and determination of a suitable methodology for planar and SPECT imagings with 223Ra

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026876

Enrollment

Registered

2017-04-26

Start date

2017-06-15

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Castration-resistant prostate cancer with bone metastases

Interventions

SPECT/CT

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: Children

Design outcomes

Primary

Measure	Time frame
Planar and SPECT imagings in 223Ra (Xofigo) therapy.	—

Countries

Japan

Contacts

Public ContactKatsuhiko Kato

Nagoya University Graduate School of Medicine Department of Radiological and Medical Laboratory Sciences

katokt@med.nagoya-u.ac.jp052-719-1504

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026